company background image
2877 logo

China Shineway Pharmaceutical Group SEHK:2877 Stock Report

Last Price

HK$9.19

Market Cap

HK$6.9b

7D

-7.1%

1Y

1.4%

Updated

22 May, 2024

Data

Company Financials +

China Shineway Pharmaceutical Group Limited

SEHK:2877 Stock Report

Market Cap: HK$6.9b

2877 Stock Overview

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance5/6
Financial Health5/6
Dividends4/6

China Shineway Pharmaceutical Group Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for China Shineway Pharmaceutical Group
Historical stock prices
Current Share PriceHK$9.19
52 Week HighHK$10.72
52 Week LowHK$6.55
Beta0.82
1 Month Change0.99%
3 Month Change1.88%
1 Year Change1.43%
3 Year Change22.37%
5 Year Change29.44%
Change since IPO90.47%

Recent News & Updates

Recent updates

Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?

May 13
Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?

China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461

Apr 26
China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461

Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?

Apr 17
Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?

China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461

Mar 31
China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461

China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings

Mar 14
China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings

Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?

Jan 29
Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?

China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly

Sep 28
China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly

China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118

Sep 01
China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118

We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Aug 03
We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?

May 30
Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?

We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Mar 07
We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125

Sep 01
China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125

China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 31
China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet

Apr 07
China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet

China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.

Mar 11
China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.

Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?

Feb 18
Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?

Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?

Jan 31
Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?

Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?

Jan 13
Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?

What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?

Dec 25
What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?

We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease

Dec 10
We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease

Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years

Nov 25
Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years

Shareholder Returns

2877HK PharmaceuticalsHK Market
7D-7.1%-2.7%1.3%
1Y1.4%-8.3%1.6%

Return vs Industry: 2877 exceeded the Hong Kong Pharmaceuticals industry which returned -8.3% over the past year.

Return vs Market: 2877 matched the Hong Kong Market which returned 1.6% over the past year.

Price Volatility

Is 2877's price volatile compared to industry and market?
2877 volatility
2877 Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement7.5%
10% most volatile stocks in HK Market15.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 2877 has not had significant price volatility in the past 3 months.

Volatility Over Time: 2877's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20023,436n/awww.shineway.com

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products; and research and development of Chinese pharmaceutical products.

China Shineway Pharmaceutical Group Limited Fundamentals Summary

How do China Shineway Pharmaceutical Group's earnings and revenue compare to its market cap?
2877 fundamental statistics
Market capHK$6.94b
Earnings (TTM)HK$1.05b
Revenue (TTM)HK$4.87b

6.6x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2877 income statement (TTM)
RevenueCN¥4.52b
Cost of RevenueCN¥1.12b
Gross ProfitCN¥3.39b
Other ExpensesCN¥2.42b
EarningsCN¥969.51m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.28
Gross Margin75.15%
Net Profit Margin21.47%
Debt/Equity Ratio4.3%

How did 2877 perform over the long term?

See historical performance and comparison

Dividends

6.3%

Current Dividend Yield

33%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.